Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Arribas, Jose R MD*; Pulido, Federico MD†
Internal Medicine Service (HIV Unit) *Hospital La Paz †Hospital Doce de Octubre Madrid, Spain
To the Editor:
Karlstrom et al1 have conducted a pilot clinical trial of boosted atazanavir monotherapy that put patients at unnecessary risk. First, they switched patients who were taking extremely simple regimens to boosted atazanavir monotherapy without knowing if patients were able to tolerate atazanavir and ritonavir. Second, they allowed patients who were receiving efavirenz or nevirapine to switch directly to boosted atazanavir monotherapy. The terminal half-life of nevirapine and efavirenz can be rather long,2 and both are potent inducers of atazanavir metabolism.3 In addition, the induction caused by nevirapine and efavirenz can persist for a number of days after these drugs are stopped. Because of this negative interaction, patients might have had low levels of atazanavir during the first 4 weeks that were missed by the researchers. Third, patients who took contraindicated medications such as ranitidine and lansoprazole were not immediately discontinued from the trial. It is quite dramatic that of the 5 observed failures, 4 occurred in patients who were switched from efavirenz and the other occurred in a patient who was switched from zidovudine plus lamivudine plus abacavir and who received ranitidine along with boosted atazanavir monotherapy.
We have conducted 2 clinical trials of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. To minimize risk for patients, we first conducted a pilot study to rule out an unacceptable rate of resistance development.4 Results of this small trial were encouraging enough to allow us to conduct an adequately powered trial.5 Forty-eight-week efficacy and resistance outcomes in the OK04 trial compare favorably with other well-accepted simplification strategies. Given these results, we consider that the statement by Karlstrom et al that monotherapy studies of boosted protease inhibitors might be unethical is unfounded. This unfair suggestion might have a negative impact on investigators and patients still enrolled in properly designed monotherapy trials. We respectfully remind Kalstrom et al that such strong statements about unethical research should be reserved for trials in which there is at least some evidence that patients are put at risk that could have been easily avoided.
Jose R. Arribas, MD*
Federico Pulido, MD†
This article has been cited 1 time(s).
© 2007 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at JAIDS Journal of Acquired Immune Deficiency Syndromes.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics